SCHEDULE: Armistice Capital Discloses 8.31% Stake in FibroGen

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.31% in FibroGen Inc., totaling 336,000 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the Reporting Persons, have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in FibroGen Inc.
• The Reporting Persons beneficially own an aggregate of 336,000 shares of FibroGen Inc. Common Stock, representing 8.31% of the class.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The shares were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of FibroGen Inc., other than activities solely in connection with a nomination under Rule 14a-11.
• The percentage of shares beneficially owned is based on 4,043,899 shares outstanding as of July 31, 2025, as reported in FibroGen's 10-Q filed on August 11, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a Schedule 13G is a factual disclosure, the presence of a significant stake by an investment firm like Armistice Capital can be interpreted as a positive signal of confidence in the company, especially given the stated passive investment intent.

Positives

• A significant institutional investor, Armistice Capital, maintains a substantial stake (8.31%) in FibroGen Inc., which can be viewed as a vote of confidence in the company's long-term prospects.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, indicating a passive investment stance.

Risks

• While the filing states the shares are not held for control purposes, any large beneficial ownership stake could potentially lead to future shareholder activism or influence on corporate decisions, even if not the stated current intent.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding FibroGen Inc.'s future operations or financial performance, focusing solely on beneficial ownership disclosure.

Industry Context

This filing reflects an investment firm's significant stake in a biotechnology company. Such disclosures are common in the biotech sector, where institutional investors often take positions based on pipeline potential, clinical trial outcomes, and market opportunities.

Comparison to Industry Standards

• The 8.31% stake held by Armistice Capital is a substantial position, indicating a high-conviction investment. For comparison, institutional ownership in biotech companies often varies widely, but a stake over 5% typically triggers reporting requirements and signifies a notable investment.
• The stated purpose of holding shares in the ordinary course of business, without intent to influence control, aligns with typical passive investment strategies employed by many hedge funds and asset managers in the biotech space, such as those seen with funds like BlackRock or Vanguard, though the percentage here is higher than typical passive index fund holdings.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may influence investor sentiment and potentially the stock price, signaling institutional interest.
• Management: Awareness of a large, passive institutional holder may influence strategic considerations, though the filing explicitly disclaims intent to influence control.

Key Dates

Keywords

FibroGen Inc., Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals